Prange Pharma has announced it has successfully completed the acquisition of the MSD Animal Health manufacturing site in Aprilia, Italy.
The acquisition was proposed in September last year.
Following the closing, the site will operate under the new name 'Aprilia Animal Health,' establishing a dedicated European contract manufacturing platform in the animal health sector.
In a statement, Prange Pharma said that the transaction marked a key milestone in its strategy to "expand its footprint in Europe," positioning itself as a "centre of excellence for global customers."
Additionally, Prange Pharma and MSD Animal Health are entering a long-term supply partnership, which the pair say will ensure continuity for existing products and a seamless transition for customers.
The facility also features a newly launched website highlighting Aprilia Animal Health's full-service offering.
Otto Prange, owner of Prange Group, commented: "This successful closing represents an important step in executing our long-term growth strategy."
Aprilia Animal Health will become a key pillar of our European manufacturing network.
Sebastian Heckerodt, Managing Director of Prange Pharma GmbH, added: "We are proud to officially welcome the Aprilia team to Prange Pharma."
Our focus is now on integration, further investment and developing Aprilia Animal Health into a leading CDMO partner for the global animal health industry.